TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Jewish Hospital chest pain center receives accreditation Jewish Hospital recently received a Cycle II accreditation from the Society of Chest Pain Centers. feeds.bizjournals.com |
Vivus: A One Trick Pony Ruthanne Williams Roussel submits:Well, Vivus's (VVUS) long-awaited one-year pivotal data for weight-loss drug Qnexa, released September 9, was great, all agree. There is a PowerPoint presentation on their web site and a slew of new articles anywhere you care to look. Placebo-adjusted, patients reached on average 11% weight loss on the higher dose of Qnexa and 5.1% on the low dose. In fact, even the low dose was so efficacious not only in terms of weight loss, but also in terms of secondary endpoints (metabolic and cardiovascular improvement) that VVUS plans to submit all three doses for approval to the FDA. Obviously, this is super for VVUS, whose shares rose 70% to approach the $12 level. Mike Huckman is also right of course when he says "weight loss ain't gonna come in a pill." The real value may lie down the road 3-5 years in indications for diabetes, hypertension and perhaps metabolic syndrome (if the docs at the FDA can ever agree on what that is exactly).Complete Story » seekingalpha.com |
Access Pharma's Prospects Look Good Even Without a Buyout VFC submits: An email from 'Marty' regarding Access Pharmaceuticals (ACCP.OB):What's your take on Access Pharma?...I'm hearing lots of takeover rumors but that's not enough to warrant a strong position. What are its prospects as a stand-alone and what are your thoughts about a possible buy out? Complete Story » seekingalpha.com |
Monday's Rx-Recap (11-02-09) Below is a list of the healthcare sector companies that made news in the healthcare sector on Monday, November 2, 2009. This list feature is meant to help investors keep tabs on the sector without having to scour through all the press releases.Bristol-Myers Squibb (NYSE:BMY) announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir.Complete Story » seekingalpha.com |
CytRx Corporation: A Solid Rebound Play? As anticipated and reported by BioMedReports on Novermber 23rd, CytRx Corporation (NASDAQ:CYTR) appears to be shaping up into quite a rebound story. Yesterday morning, officials at the company have announced that they are permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol. “We are delighted with the FDA’s decision to approve a protocol that provides a safe and efficient avenue to ascend arimoclomol dosing to the target dosage level of 400 mg three times daily, which we believe will prove most effective in treating ALS patients,” said CytRx President and CEO Steven A. Kriegsman.Complete Story » seekingalpha.com |